Efficacy of High-Dose Dual Therapy Versus Bismuthcontaining Quadruple Therapy for First-Line Treatment of Helicobacter Pylori Infection and an Interim Report of Multi-Center, Randomized Control Study

Hu, Chi-Tan; Tung, Chien‐Chih; Lin, Chan‐Yu; Kuo, I-Nan; Lin, Bor-Ru; Wang, Honglong; Chen, Jin-De; Cheng, Mu-Liang; Shun, Chia‐Tung; Li, Huei-Mi; Hung, Jui‐Sheng; Lei, Wei‐Yi; Shieh, Ming Jium; Wong, Jau‐Min; Kao, John Y.; Yang, Jyh‐Chin

doi:10.1016/s0016-5085(17)30921-6

Cited by 13 publications

(62 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 – 40 The characteristics of the included trials are shown in Table 1 . Of the 15 trials, 11 were conducted in Asia, 29 – 33 , 35 – 40 3 in Europe, 27 , 28 , 34 and 1 in North America. 26 HDDT was given three times daily in four trials, 26 , 28 , 30 , 34 and four times daily in the others.…”

Section: Resultsmentioning

confidence: 99%

“… 26 HDDT was given three times daily in four trials, 26 , 28 , 30 , 34 and four times daily in the others. 27 , 29 , 31 – 33 , 35 – 40 Six trials used TT, 26 , 28 – 31 , 36 seven used BQT, 27 , 33 – 35 , 37 , 38 , 40 one used non-BQT, 39 and one used both TT and ST as control regimen. 32 Nine trials recruited treatment-naive patients, 30 , 33 – 40 four recruited treatment-experienced patients, 27 – 29 , 31 one recruited both, 32 and one did not report treatment experience of included patients.…”

Section: Resultsmentioning

confidence: 99%

“… 27 , 29 , 31 – 33 , 35 – 40 Six trials used TT, 26 , 28 – 31 , 36 seven used BQT, 27 , 33 – 35 , 37 , 38 , 40 one used non-BQT, 39 and one used both TT and ST as control regimen. 32 Nine trials recruited treatment-naive patients, 30 , 33 – 40 four recruited treatment-experienced patients, 27 – 29 , 31 one recruited both, 32 and one did not report treatment experience of included patients. 26 Of the 15 included trials, 12 were published as full-length articles, 26 – 34 , 37 – 39 whereas 3 were conference abstracts.…”

Section: Resultsmentioning

confidence: 99%

“… 26 Of the 15 included trials, 12 were published as full-length articles, 26 – 34 , 37 – 39 whereas 3 were conference abstracts. 35 , 36 , 40 …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis

Zhu

Zhang

Wang

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Helicobacter pylori resistance to amoxicillin remains rare in many regions. Proton pump inhibitor-amoxicillin-containing high dose dual therapy (HDDT) has been proposed to treat H. pylori infection. We aimed to assess the effectiveness and safety of PPI-amoxicillin HDDT for treatment of H. pylori infection in comparison with other regimens. Methods: Databases, including PubMed, Embase, and the Cochrane Register of Controlled Trials, were searched to find relevant publications. Randomized controlled trials comparing HDDT with control regimens for H. pylori eradication in adult patients were included. The primary outcome was eradication rate by intention-to-treat analysis. Adverse events were analyzed as second outcome. Results: A total of 15 trials with 3818 patients qualified for inclusion. The eradication rate of HDDT was neither significantly inferior nor superior to the recommended regimens such as triple therapy, bismuth quadruple therapy, and non-bismuth quadruple therapy [relative risk (RR): 1.00, 95% confidence interval (CI): 0.96–1.05, p = 0.870]. This finding was robust through subgroup analyses and sensitivity analyses. Trial sequential analysis showed that HDDT was equivalent to control regimens, and further similar trials were unlikely to alter the conclusions of this analysis. The frequency of adverse events was significantly lower in HDDT group (RR: 0.48, 95% CI: 0.37–0.64, p < 0.001). Conclusion: HDDT was equivalent to recommended first-line or rescue regimens with fewer adverse effects. The evidence from this meta-analysis supports the use of HDDT as first-line or rescue treatment for H. pylori infection. Trial registration: PROSPERO CRD42019133002

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“… 26 Of the 15 included trials, 12 were published as full-length articles, 26 – 34 , 37 – 39 whereas 3 were conference abstracts. 35 , 36 , 40 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis

Zhu

Zhang

Wang

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…[11–14] The actual efficacy of amoxicillin/PPI dual therapy that has been used in several areas remains controversial partly because of differences in doses and dosing frequency. [13,15–35] Actually, high-dose dual therapy (HDDT), defined as amoxicillin ≥2.0 g/day, amoxicillin or PPI gave 3 or 4 times daily, or administration of both amoxicillin and PPI 4 times daily for 14 days, has resulted in greater efficacy (i.e., over 90%). [32,34–38] Several clinical trials have reported the H pylori eradication rates of the HDDT compared with BQT.…”

Section: Introductionmentioning

confidence: 99%

High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment

et al. 2019

View full text Add to dashboard Cite

show abstract

Dual therapy for Helicobacter pylori infection

Duan

Liu

Zuo

2023

Chinese Medical Journal

View full text Add to dashboard Cite

Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China, dual therapy (DT) comprising an acid suppressor and amoxicillin has also been recommended. In recent years, the eradication rate of H. pylori has reached >90% using DT, which has been used not only as a first-line treatment but also as a rescue treatment. Compared with BQT, DT has great potential for H. pylori eradication; however, it has some limitations. This review summarizes the development of DT and its application in H. pylori eradication. The H. pylori eradication rates of DT were comparable to or even higher than those of BQT or standard triple therapy, especially in the first-line treatment. The incidence of adverse events associated with DT was lower than that with other therapies. Furthermore, there were no significant differences in the effects of dual and quadruple therapies on gastrointestinal microecology. In the short term, H. pylori eradication causes certain fluctuations in the gastrointestinal microbiota; however, in the long term, the gastrointestinal microbiota eventually returns to its normal state. In the penicillin-naïve population, patients receiving DT have a high eradiation rate, better compliance, lower incidence of adverse reactions, and lower primary and secondary resistance to amoxicillin. These findings suggest the safety, efficacy, and potential of DT for H. pylori eradication.

show abstract

Efficacy of High-Dose Dual Therapy Versus Bismuthcontaining Quadruple Therapy for First-Line Treatment of Helicobacter Pylori Infection and an Interim Report of Multi-Center, Randomized Control Study

Cited by 13 publications

References 0 publications

High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis

High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis

High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment

Dual therapy for Helicobacter pylori infection

Contact Info

Product

Resources

About